Drug Combination Details

General Information of the Combination (ID: C97546)
Name Silibinin   NP Info  + Erlotinib   Drug Info 
Structure +
Disease
Lung cancer [ICD-11: 2C25]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Reversing Drug Resistance by This Combination
                 Reversing Drug Resistance     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression EGFR  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation ERK1  Molecule Info 
Pathway MAP
                    In-vitro Model A-549 CVCL_0023 Lung adenocarcinoma Homo sapiens
NCI-H460 CVCL_0459 Lung large cell carcinoma Homo sapiens
NCI-H1299 CVCL_0060 Lung large cell carcinoma Homo sapiens
NCI-H1975 CVCL_1511 Lung adenocarcinoma Homo sapiens
HCC827 CVCL_2063 Lung adenocarcinoma Homo sapiens
LK2 CVCL_W132 Ovarian carcinoma Homo sapiens
PC-9 CVCL_B260 Lung adenocarcinoma Homo sapiens
293T GNE CVCL_0V13 Healthy Homo sapiens
                    In-vivo Model Tumors were grown by implanting 5*106 cells in Matrigel into female SCID mice flanks.
                    Experimental
                    Result(s)		 Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
References
Reference 1 Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther. 2010 Dec;9(12):3233-43.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link